Emcure Pharmaceuticals Receives USFDA Inspection Report; Facility Classified as VAI
Emcure Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) regarding an inspection of its formulations facility. The inspection, which took place between May 06, 2026, and May 15, 2026, at the company's location in G.I.D.C., Taluka - Sanand, Ahmedabad -382110, Gujarat, resulted in a classification of Voluntary Action Indicated (VAI).The USFDA inspection was conducted on the formulations facility located in Sanand, Ahmedabad. Following the review process, Emcure Pharmaceuticals confirmed that it has received the official Establishment Inspection Report from the regulatory body.
As per the outcome detailed by the company, the USFDA classified the inspection status of the Sanand facility as Voluntary Action Indicated (VAI). With this classification, the inspection is now considered closed.
EMCURE Stock Price Movement
Emcure Pharmaceuticals Limited closed higher on Friday, with shares gaining 2.34% and settling at ₹1978.40. The strong advance saw the stock achieve a significant milestone by hitting its 52-week high amid trading of 145,070 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.